



**Uscom**

## ASX MEDIA RELEASE

### H1 Market Update – FY 21 (5 mths) v FY 20 (6 mths)


Sales \$2.01M up 196% from \$0.68M

Revenue \$2.26M up 135% from \$0.96M

Profit \$0.18M up from -\$1.5M

Cash inflow \$0.21M up from -\$0.78M

**SYDNEY, Australia, Wednesday 9<sup>th</sup> December 2020:** Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today notified the market of significant changes to trading conditions in the first 5 months of the H1 reporting period of FY 2021, compared to the complete 6 months of H1 in FY 2020, the prior corresponding period (pcp).



Comparison of results from 6 months in FY 2020 and the first 5 months in H1 FY 2021 (\* incomplete 5 month period)

Unaudited management accounts of Uscom Limited for the first 5 months of FY 2021 demonstrate a significant increase in sales revenue, total revenue, profit and cash inflow compared with the complete 6 months of H1 in FY 2020, the pcp. Sales revenue of \$2.01M was up 196% from \$0.68M, with total revenue of \$2.26M, up 135% from \$0.96M previously. Profit for the 5 months was \$0.18M, increased from a loss of \$1.5M, while operating cash inflow for the 5 months was \$0.21M, increased from an outflow of \$0.78M after correcting for the capital raising of \$1.05M in November 2020 in the pcp.

Executive Chairman of Uscom, Professor Rob Phillips said *“Uscom has updated the market of significantly changed financial results consistent with its continuous disclosure obligations.”*

Uscom manufactures and markets the **USCOM 1A**, the Uscom **BP+**, and the Uscom **SpiroSonic** digital ultrasonic spirometry technologies and the **VENTITEST** and **VENTITEST-S** ultrasonic ventilator calibration devices for optimising respiratory device performance.



**Uscom**

## ASX MEDIA RELEASE

### About Uscom

**Uscom Limited (UCM):** An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

**The USCOM 1A:** A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

**The Uscom BP+:** A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary

**BP+ Reporter,** an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

**Uscom SpiroSonic digital multi-path ultrasonic spirometers:** High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance.

**VENTITEST** digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

### Uscom Contacts

Rob Phillips  
Chairman  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

Brett Crowley  
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.